Skip to content
Federal Election, Medical Health Aged Care

Pain relief medicines ‘Made in Australia’ it just makes sense

Palliative Care Australia 2 mins read

Australian made IV fluids will be a huge step forward in establishing an Australian-made  supply of critical health products, but we should be aiming higher and adding pain relief medications to our ‘Made in Australia’ plans.

Palliative Care Australia (PCA) has welcomed news that the Federal Government will invest $20 million to expand the local manufacturing of IV (intravenous) fluids, partnering with Baxter Healthcare to grow their existing facility in Western Sydney.

“Ongoing shortages of IV fluids have been a huge concern for clinicians since 2023, but over the same time frame, even longer in some case, we have seen heartbreaking shortages of pain relief medications for people of all ages at the end of life,” says Camilla Rowland, Chief Executive Officer, Palliative Care Australia.

“In the same way that government and industry are now investing in local production to solve the IV fluids shortage, we need to do the same for pain relief medications so that people can die with peace and dignity, and so families aren’t left with the trauma of seeing loved ones in pain and distress.”

Australia already has a role in global production. Tasmania is the world’s largest producer of the raw ingredient needed for many of these medicines – poppies.

​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​Poppies are grown to extract a material known as ‘alkaloid’ which is a core ingredient in a range of pain relief pharmaceuticals including morphine, thebaine and codeine.

According to the Tasmanian Department of Natural Resources and Environment, Tasmania’s 450 poppy growers supply almost half of the world’s demand of the alkaloid material.

“This is a significant competitive advantage for Australia as global supply chains falter and business models are challenged,” Ms Rowland says.

“Our experience during covid also demonstrates that we have the skills and capacity to manufacture vaccines locally – at that time we were able to have some independence from supply shortages and global transport challenges and look after our own.

“A future made in Australia must include medicines. Using Australian grown poppies to make pain relief medications for Australians just makes sense.”

With the support of six other leading health and care organisations, PCA has presented an 11 point plan to the Health Minster, to resolve the ongoing shortage of pain relief medications.

“Apart of making these medicines in Australia we are also advocating for a national stockpile to be established and for pharmaceutical companies to give more notice of impending shortages,” Ms Rowland says.

“We want to be partners in solving an issue that has gone on for too long. The wider community is also calling for action, with close to 35,0000 signatures on our ‘Better access to palliative care’ petition.

“We remain hopeful that those who want to make up the 48th parliament of Australia will respond and work with us to fix this so that quality of life at the end of life can be delivered to every Australian.”

The following organisations have developed and are fully supportive of the 11 point plan to resolve medicine shortages:

  • Palliative Care Australia
  • Australia New Zealand Society of Palliative Medicine
  • Advanced Pharmacy Australia
  • Pharmaceutical Society of Australia
  • Palliative Care Nurses Australia
  • Pain Australia
  • Aged and Community Care Providers Association

The 11 point plan forms part of Palliative Care Australia’s 2025 Federal Election Platform and can be viewed and downloaded HERE.


Contact details:

Ian Campbell

P: 0417 482 171

E: [email protected]

Media

More from this category

  • Medical Health Aged Care
  • 18/12/2025
  • 22:11
BeOne Medicines Ltd.

BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma

BGB-B2033 is a bispecific antibody directed at GPC3 and 4-1BB; key targets in the most common liver cancer FDA Fast Track Designation reflects the…

  • Contains:
  • Medical Health Aged Care
  • 18/12/2025
  • 19:11
Takeda Pharmaceutical Company Limited

Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment

Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half…

  • Contains:
  • Medical Health Aged Care
  • 18/12/2025
  • 12:24
La Trobe University

Cell death discovery could aid cancer treatments

LaTrobe researchers have made a groundbreaking discovery about the way dying cells are cleared from our bodies, which could have important impacts on recovery from diseases including cancer infection and inflammatory diseases. Traditionally, it was believed dying cells were broken into smaller pieces by the cell’s own internal machinery, enabling the pieces to be more easily removed from the body. However the study, led by scientists at the La Trobe Institute for Molecular Science and Research Centre for Extracellular Vesicles found that the process of dying cell fragmentation is actually assisted by neighbouring cells. Published in Science Advances, the study…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.